Form D · Pharmaceuticals
Renibus Therapeutics, Inc.
Southlake, TX · CIK 0001667699
Offering snapshot reported Jul 17, 2025 · SEC filing
- Reported sold
- $111M Offering amount: $111M
- Investors reported
- 59 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 25, 2023 As reported in this filing
Fundraising history
Reported soldDates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.
What changed?
Latest filing versus its linked predecessor, where available.
- Reported sold$95,905,859 → $110,895,239
- Reported investors57 → 59
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 17, 2025 | Amendment | $110,895,239 | $14,989,380vs Sep 18, 2023 | 59 | SEC filing |
| Sep 18, 2023 | Amendment | $95,905,859 | $32,100,359vs Jun 9, 2023 | 57 | SEC filing |
| Jun 9, 2023 | Initial | $63,805,500 | No comparison | 37 | SEC filing |
| Aug 22, 2022 | Amendment | $23,413,102 | $8,487,000vs Jul 29, 2022 | 18 | SEC filing |
| Jul 29, 2022 | Initial | $14,926,102 | No comparison | 17 | SEC filing |
| Feb 18, 2022 | Amendment | $34,614,335 | $18,361,156vs Nov 19, 2019 | 30 | SEC filing |
| Jul 15, 2020 | Amendment | $19,750,184 | $16,376,176vs Sep 23, 2019 | 18 | SEC filing |
| Nov 19, 2019 | Amendment | $16,253,179 | $12,879,171vs Sep 23, 2019 | 13 | SEC filing |
| Sep 23, 2019 | Initial | $3,374,008 | No comparison | 8 | SEC filing |
| May 2, 2016 | Amendment | $10,919,000 | $715,000vs Apr 12, 2016 | 112 | SEC filing |
| Apr 12, 2016 | Amendment | $10,204,000 | $1,877,500vs Mar 23, 2016 | 101 | SEC filing |
| Mar 23, 2016 | Amendment | $8,326,500 | $5,429,000vs Feb 24, 2016 | 81 | SEC filing |
| Feb 24, 2016 | Initial | $2,897,500 | No comparison | 28 | SEC filing |
| Feb 23, 2016 | Initial | $300,000 | No comparison | 4 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $148K (estimated)
- Form D file number
- 021-483766
Amounts listed include amounts from certain converting SAFEs, which may have been previously reported on Form D, and certain warrants (see Item 15). The SAFEs converted into Series B-1 Preferred Stock at the initial closing of the transaction.
Issuer paid placement agent cash fee of 1% of aggregate amount of proceeds from sale of Series B Preferred from 06/06/2025 to 06/17/2025 and issued placement agent warrants to purchase up to 96,971 shares of Common Stock (exercise price per share, $1.61).
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Salem Partners LLC | 43363 |
Source: Form D, filed Jul 17, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Nels Bergmark | Executive |
| Jamie Donadio | Executive |
| Alvaro Guillem | Director |
| Carlos Guillem | Director |
| Dale Jones | Director |
| Harpreet Kaur | Director, Executive |
| Jocelyn Keyser | Director |
| D. Jeffrey Keyser | Director, Executive |
| Henrik Rasmussen | Director |
| Jennifer D. Rasmussen | Director |
| Bhupinder Singh | Director, Executive |
| Frank Stonebanks | Director, Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:Southlake, TX, 76092
Phone: 386-527-1071